$0.18
2.76% today
Nasdaq, Apr 04, 08:43 pm CET
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

GlycoMimetics, Inc. Stock price

$0.19
-0.07 28.45% 1M
+0.02 15.54% 6M
-0.06 25.66% YTD
-2.58 93.31% 1Y
-0.94 83.55% 3Y
-1.92 91.23% 5Y
-8.11 97.77% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.02 11.73%
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

Key metrics

Market capitalization $11.94m
Enterprise Value $1.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.25
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-32.51m
Free Cash Flow (TTM) Free Cash Flow $-31.11m
Cash position $10.72m
EPS (TTM) EPS $-0.59
Short interest 4.84%
Show more

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

Hold
100%

Financial data from GlycoMimetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
95% 95%
-
-0.04 -0.04
95% 95%
-
- Selling and Administrative Expenses 18 18
3% 3%
-
- Research and Development Expense 14 14
29% 29%
-
-32 -32
16% 16%
-
- Depreciation and Amortization 0.04 0.04
95% 95%
-
EBIT (Operating Income) EBIT -33 -33
17% 17%
-
Net Profit -38 -38
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlycoMimetics, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D.
Neutral
PRNewsWire
about one month ago
NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)'s  sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to lea...
Neutral
GlobeNewsWire
about one month ago
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors
More GlycoMimetics, Inc. News

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 26
Founded 2003
Website www.glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today